Pharmacokinetics of intramuscular microparticle depot of valdecoxib in an experimental model Pharmacokinetics of intramuscular microparticle depot

Drug Development and Industrial Pharmacy

Volumn 35, Issue 9, 2009, Pages 1043-1047

  Agnihotri, Sagar M ^a   Vavia, Pradeep R ^a  

^a UNIVERSITY OF MUMBAI   (India)

Author keywords

Bioavailability; Depot formulation; Pharmacokinetics; Poly lac(glc leu) ; Valdecoxib

Indexed keywords

GLYCOLIC ACID; LEUCINE; POLYLACTIC ACID; VALDECOXIB;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG STORAGE; ENCAPSULATION; EXPERIMENTAL MODEL; MAXIMUM PLASMA CONCENTRATION; MEMBRANE MICROPARTICLE; NONHUMAN; RABBIT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE 2 INHIBITORS; DATA INTERPRETATION, STATISTICAL; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCIPIENTS; HALF-LIFE; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; RABBITS; SULFONAMIDES;

EID: 70349283196     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040902762979     Document Type: Article

References (19)

1. Camu F, Beecher T, Recker DP, Verburg KM. (2002). Valdecoxib a COX-2-specific inhibitor is an efficacious opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther, 9:43-51.
2. Fricke J, Varkalis J, Zwillich S, Adler R, Forester E, Recker DP, et al. (2002). Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther, 9:89-97.
3. Donnelly MT, Hawkey CJ. (1997). COX-2 inhibitors-a new generation of safer NSAIDs. Aliment Pharmacol Ther, 11:227-236
4. Pennisi E. (1998). Building better aspirin and does aspirin ward off cancer and Alzheimer's. Science, 280:1191-1192
5. Vane JR, Bakhle YS, (1998). Botting RM. Cyclooxygense 1 and 2. Annu Rev Pharmacol Toxicol, 38:97-120.
6. Isakson PC, Zweifel BS, Masferrer JL, Koboldt C, Seibert K, Hubbard RC, et al. (1998). Specific COX-2 inhibitors: From bench to bedside. In: Vane J, Botting J, eds. Pharmacology, clinical effects and therapeutic potential. London: Kluwer Academic Publishers and William Harvey Press, 127-133
7. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD et al. (1998). Preliminary study of the safety and efficacy of SC-58635 a novel cycolooxygenase 2 inhibitor. Arthritis Rheum, 41:1591-1602.
8. Tuncay M, Calis S, Kas HS, Ercan MT, Peksoy I, Hincal AA. (2000). In vitro and in vivo evaluation of diclofenac sodium loaded albumin microspheres. J Microencapsul, 17(2):145-155
9. Tuncay M, Calis S, Kas HS, Ercan MT, Peksoy I, Hincal AA. (2000). Diclofenac sodium incorporated PLGA (50:50) microspheres: Formulation considerations and in vitro/in vivo evaluation. Int J Pharm, 195(1-2):179-188
10. Puebla P, Pastoriza P, Barcia E, Fernandez-Carballido A. (2005). PEG-derivative effectively modifies the characteristics of indomethacin-PLGA microspheres destined to intra-articular administration. J Microencapsul, 22(7):793-808.
11. Srinath P, Chary MG, Vyas SP, Diwan PV. (2000). Preparation and pharmacodynamic evaluation of liposomes of indomethacin. Drug Dev Ind Pharm, 26(3):313-321
12. Srinath P, Chary MG, Vyas SP, Diwan PV. (2000). Long-circulating liposomes of indomethacin in arthritic rats-a biodisposition study. Pharm Acta Helv, 74(4):399-404.
13. Rajendrakumar K, Madhusudan S, Pralhad T. (2005). Cyclodextrin complexes of valdecoxib: Properties and antiinflammatory activity in rat. Eur J Pharm Biopharm, 60(1):39-46.
14. Agnihotri SM, Vavia PR. (2006). Effects of formulation variables on the formation of nanoparticles prepared from L-lactide-depsipeptide copolymer. J Biomed Nanotech, 2(3-4):239-244
15. Tuncay M, Alis SC, Kas HS, Ercan MT, Peksoy I, Hincal AA. (2000). Diclofenac sodium incorporated PLGA (50:50) microspheres: Formulation considerations and in vitro: In vivo evaluation. Int J Pharm, 195:179-188
16. Ramakrishna NVS, Vishwottam KN, Wishu S, Koteshwara M. (2004). Quantitation of valdecoxib in human plasma by highperformance liquid chromatography with ultraviolet absorbance detection using liquid-liquid extraction. J Chromatogr B, 802(2):271-275
17. Casley-Smith JR. (1964). An electron microscopic study of injured and abnormally permeable lymphatics. Ann NY Acad Sci, 116:803-830
18. Naeff R, Pliska V, Weder HG. (1990). Pharmacokinetics of small unilamellar liposomes and incorporated lonazolac after i.m. administration. J Microencapsulation, 7(1):95-103.
19. Pandey R, Khuller GK. (2004). Subcutaneous nanoparticlebased antitubercular chemotherapy in an experimental model. J Antimicrob Chemother, 54:266-268